Filter Results
:
(53)
Show Results For
- All HBS Web (53)
- Faculty Publications (19)
Show Results For
- All HBS Web (53)
- Faculty Publications (19)
- September 2022
- Article
Giving a Buck or Making a Buck? Donations by Pharmaceutical Manufacturers to Independent Patient Assistance Charities
By: Leemore Dafny, Christopher Ody and Teresa Rokos
The federal Anti-Kickback Statute prohibits biopharmaceutical manufacturers from directly covering Medicare enrollees’ out-of-pocket spending for the drugs they manufacture, but manufacturers may donate to independent patient assistance charities and earmark donations...
View Details
Keywords:
Cost Sharing;
Prescription Drugs;
Drug Spending;
Medicare;
Dual Eligibility;
Cost;
Health Care and Treatment;
Philanthropy and Charitable Giving;
Pharmaceutical Industry
Dafny, Leemore, Christopher Ody, and Teresa Rokos. "Giving a Buck or Making a Buck? Donations by Pharmaceutical Manufacturers to Independent Patient Assistance Charities." Health Affairs 41, no. 9 (September 2022).
- 27 Sep 2011
- First Look
First Look: September 27
terms expire, changes to the U.S. healthcare system are also of significance to patients and the pharmaceutical industry internationally. This article evaluates how the ACA will affect the size of the View Details
Keywords:
Sean Silverthorne
- 2010
- Working Paper
Boundary Spanning in a For-profit Research Lab: An Exploration of the Interface Between Commerce and Academe
By: Christopher C. Liu and Toby E. Stuart
In innovative industries, private-sector companies increasingly are participants in open communities of science and technology. To participate in the system of exchange in such communities, firms often publicly disclose what would otherwise remain private discoveries....
View Details
Keywords:
For-Profit Firms;
Higher Education;
Information Publishing;
Innovation and Invention;
Science-Based Business;
Social and Collaborative Networks;
Boundaries;
Biotechnology Industry;
Biotechnology Industry
Liu, Christopher C., and Toby E. Stuart. "Boundary Spanning in a For-profit Research Lab: An Exploration of the Interface Between Commerce and Academe." Harvard Business School Working Paper, No. 11-012, August 2010.
- Web
Faculty & Advisors - MBA
acquisition of Guidant, Vertex in its acquisition of Aurora and Illumina in its purchase of Solexa. Since joining Centerview in 2009, the firm has been a leading advisor to the global Biopharmaceutical View Details
- Web
Sample Student Projects - Institute For Strategy And Competitiveness
Biopharmaceutical Cluster (2009) Bangalore Biotechnology (2008) Gujarat Diamonds (2008) Bollywood — Maharashtra and India’s Film Cluster (2008) Karnataka Offshore IT and Business Process Outsourcing Services Cluster (2006) Indonesia Bali...
View Details
- Web
African American Student Union Spotlight on Joint Degrees - MBA
Blog Blog MBA Voices Filter Results Arrow Down Arrow Up Read posts from Author Alumni Author Career and Professional Development Staff Author HBS Community Author HBS Faculty Author MBA Admissions Author MBA Students Topics Topics 1st Year (RC) 2+2 Program 2nd Year...
View Details
- Web
Pharmaceuticals | Baker Library | Bloomberg Center | Harvard Business School
development. News and Journals Contract Pharma /citations/contract-pharma Provides the pharmaceutical and biopharmaceutical industry with the most up-to-date news, outsourcing information, business trends,...
View Details
- Web
Academics - Health Care
interests in organizations that provide health care (e.g., hospitals, medical groups, retail clinics) or in firms that partner with, supply, consult to, or invest in such organizations (e.g., payers, biopharmaceutical and device...
View Details
- 27 Mar 2012
- First Look
First Look: March 27
Corp. (B) Regina E. Herzlinger and Natalie KindredHarvard Business School Supplement 311-087 This case, the denouement to "PAREXEL International Corp. (A)," describes developments at PAREXEL and the biopharmaceutical View Details
Keywords:
Carmen Nobel
- Web
Informa (In Vivo, MedTech Insight, Scrip) | Baker Library | Bloomberg Center | Harvard Business School
platform. Related Resources Medical Devices Pharmaceuticals Database AttributesCoverageIn Vivo - latest 3 months; MedTech - Most recent 1 year(s) 6 month(s) available; Start-up?Categories Industry Specific Databases View Details
- Fast Answer
R&D expenditures: Companies
- R&D Activity Data series European Commission - Economics of Industrial Research and Innovation R&D Monitor See also (in print): Research & Development Growth Trends In print: Ref T176 .R25 in...
View Details
- 22 Jul 2014
- First Look
First Look: July 22
Corporate Finance Attracting Long-Term Investors Through Integrated Thinking and Reporting: A Clinical Study of a Biopharmaceutical Company By: Knauer, Andrew, and George Serafeim Abstract—Faced with a large percentage of investors that...
View Details
Keywords:
Sean Silverthorne
- 13 Oct 2016
- News
Adding Muscle to the Fight Against Disease
If you are one of the 17 million people who participated in the Ice Bucket Challenge a couple of summers ago, the money you helped raise to support ALS research may be at work today in a late-stage biopharmaceutical company headed by...
View Details
Keywords:
Deborah Blagg
- 24 Jun 2008
- First Look
First Look: June 24, 2008
Patenting on the Rate, Quality, and Direction of (Public) Research Output Authors: Pierre Azoulay, Waverly Ding, and Toby E. Stuart Periodical: Journal of Industrial Economics (forthcoming) Abstract We examine the influence of faculty...
View Details
Keywords:
Martha Lagace
- 28 Jul 2015
- First Look
First Look: July 28, 2015
country-level factors that limit firms' use of selective disclosure by intensifying scrutiny on them and by diffusing global norms to their headquarters countries. We test our hypotheses using a novel panel dataset of 4,750 public companies across many View Details
Keywords:
Carmen Nobel
- 22 Aug 2006
- First Look
First Look: August 22, 2006
is a need for a fund like this at the time of the case. Supports discussion of specialized versus generalized venture capital funds. Purchase this case: http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=805075 John Moran and the Orthopedics View Details
Keywords:
Martha Lagace
- 01 May 2007
- First Look
First Look: May 1, 2007
possibility that the effects of FDI differ by sector. Second, we differentiate FDI based on objective qualitative industry characteristics including the average skill intensity and reliance on external capital. Third, we use a new dataset...
View Details
Keywords:
Sean Silverthorne
- 17 Mar 2009
- First Look
First Look: March 17, 2009
Agreements in Bio-Pharmaceuticals Authors:Juan Alcácer, John Cantwell, and Michelle Gittelman Publication:In Location of Biopharmaceutical Activity, edited by Iain M. Cockburn and Matthew J. Slaughter. NBER, forthcoming. Abstract As the...
View Details
Keywords:
Martha Lagace
- 16 Dec 2014
- First Look
First Look: December 16
Stages of Innovation Through the lens of biopharmaceutical contract research organization (CRO) PAREXEL, this case traces the evolution of the firm as it reinvents itself in response to the transformation of the CRO sector from a small,...
View Details
Keywords:
Sean Silverthorne
- 11 May 2010
- First Look
First Look: May 11
this case:http://cb.hbsp.harvard.edu/cb/product/610031-PDF-ENG Revitalizing Dell Jan W. RivkinHarvard Business School Case 710-442 Dell Inc., with its vaunted Direct Model, defined success in the personal computer industry for more than a...
View Details
Keywords:
Martha Lagace